The file's text, extracted by GovTribe without its formatting.
Questions and Answers IFB #2026 Trikafta Please review the Amended IFB document, as it has been updated to coincide with the responses below. The bid due date has also been updated.
| Q1 |
| Confirm total annual quantity (number of 28-day cycles) and whether this is limited to one individual |
| A1 |
| Please see updated Section 2.2 Product/Service Specification. This request is for medication to be delivery for up to 18 months. The medication will be ordered on 28-day cycles, and OCFS will place monthly orders consecutively so there are no gaps in medication being provided to the individual in OCFS custody on a daily basis. There is no guarantee of quantity, as stated in the procurement, this is our best estimate at this time. This request is for one individual, if the individual is released from OCFS custody, there will no longer be a need for OCFS to purchase this medication. |
| Q2 |
| Pick-up and delivery location details (in-state NYC, elsewhere in NY, or out-of-state) and any specific site requirements |
| A2 |
| The delivery location is indicated in section 2.3 Delivery. |
| Q3 |
| Delivery expectations, including timing, scheduling, and temperature-controlled shipping |
| A3 |
| Delivery would be accepted between 8a-6p. Scheduling for the next monthly shipment should be completed within 7-10 days of the end of the current prescription and would be requested by OCFS personnel who will be identified upon Purchase Authorization contract start. Temperature controlled shipping would be expected according to the prescription’s medication profile. |
| Q4 |
| Responsibilities for expedited shipments |
| A4 |
| Bid price must include all costs associated with providing and delivering the requested medication. Scheduling for the next required monthly shipment should be completed 7-10 days before the end of the current prescription, as a result, there should not be a need for expedite shipment. |
| Q5 |
| Pricing structure (fixed vs. variable) and any allowable adjustments |
| A5 |
| The awarded bid pricing structure will remain a fixed monthly cost, with no adjustments |
| Q6 |
| Billing process, reimbursement source, and payment terms |
| A6 |
| Please refer to Section 4.3 Method of Payment for billing, reimbursement, and payment concerns. |
| Q7 |
| Required licenses and compliance obligations (NY pharmacy, Medicaid, HIPAA, reporting) |
| A7 |
| See updated 2.1 Eligible Bidders in the IFB regarding license obligation. All other obligations will be discussed with the awardee upon Purchase Authorization contract start. |
| Q8 |
| Contract term, renewal options, and termination provisions |
| A8 |
| Term of the Purchase Authorization contract will be up to 18 months. There is no guarantee of quantity, as stated in the procurement, this is our best estimate at this time. There are no renewal options. If the individual is released from OCFS custody earlier than the anticipated 18-month period, OCFS will no longer purchase this medication. |
| Q9 |
| Insurance requirements and liability expectations1010 |
| A9 |
| Please see section 4.14 Insurance Requirements through section 4.14.4 Other Insurance section of the IFB. |
| Q10 |
| Approved sourcing requirements (manufacturer/distributor) |
| A10 |
| Please see updated 2.1 Eligible Bidders. |
| Q11 |
| Evaluation criteria and key factors for award |
| A11 |
| Please see section 4.1 Method of Award section. |